ALRN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 20:45):

Stats
Šios dienos apimtis	90 485.00
Vidutinė apimtis	80 898.00
Rinkos kapitalizacija	65.28M
EPS	$0 ( 2024-04-01 )
Kita pelno data	( $-0.160 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.130
ATR14	$0.0210 (0.54%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-29	University Of Texas/texas Am Investment Management Co	Sell	6 680	Common Stock
2024-04-29	University Of Texas/texas Am Investment Management Co	Sell	274	Common Stock
2024-04-29	University Of Texas/texas Am Investment Management Co	Sell	100	Common Stock
2024-04-29	University Of Texas/texas Am Investment Management Co	Sell	3 231	Common Stock
2024-04-29	University Of Texas/texas Am Investment Management Co	Sell	13	Common Stock

INSIDER POWER
-83.63
Last 98 transactions
Buy: 23 716 503 \| Sell: 1 197 151

Tūris Koreliacija

Ilgas: 0.12 (neutral)

Trumpas: 0.99 (very strong)

Signal:(60.287) Expect same movement, but be aware

Aileron Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
TTOO	0.931
DCRC	0.918
BNIXU	0.918
JRJC	0.912
REVB	0.91
AVIR	0.909
IMPL	0.908
IMV	0.908
JFU	0.899
LSXMA	0.899

10 Labiausiai neigiamai susiję koreliacijos
CSII	-0.934
ATCX	-0.932
PAE	-0.931
MELI	-0.93
KIN	-0.926
NYMTZ	-0.922
SCR	-0.919
PCYG	-0.918
ZIXI	-0.915
HPK	-0.913

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Aileron Therapeutics Inc Koreliacija - Valiuta/Žaliavos

-0.64
( weak negative )

-0.69
( moderate negative )

0.00
( neutral )

-0.78
( moderate negative )

-0.66
( moderate negative )

0.89
( strong )

Aileron Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-119 000 (0.00 %)
EPS:	$-3.42

FY	2023
Pajamos:	$0
Bruto pelnas:	$-119 000 (0.00 %)
EPS:	$-3.42

FY	2022
Pajamos:	$0
Bruto pelnas:	$-169 000 (0.00 %)
EPS:	$-5.95

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-13.31

Financial Reports:

No articles found.

Aileron Therapeutics Inc

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.